Starling Oncology, Inc. (STLN) stock
Close on Nov 11, 2026Market cap $428.05MP/E –Yield –
Starling Oncology, Inc. grew revenue 34.6% to $620.45M over the twelve months to Sep 30, 2026. Free cash flow was $18.83M. At the latest close the market valued the company at $428.05M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $428.05M
- P/E ratio
- –
- Price to sales
- 0.69
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 4.40%
Fundamentals
- Revenue
- $620.45M
- Net income
- -$35.54M
- EPS, diluted
- -$0.29
- Free cash flow
- $18.83M
- Book value per share
- -$0.36
- Diluted shares
- 105M
Trading
- Next earnings
- Mar 11, 2027 (estimated, during market hours)
- Previous close
- $4.34
- Open
- $4.81
- Day's range
- $4.16 – $4.81
- Volume
- 2,978,900
- Average volume (20 days)
- 3,185,948
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 1.72
- 52-week range
- $2.32 – $7.13
- RSI (14 days)
- 33.3
- Volatility (1 year)
- 92.9%
- Relative volume
- 1.57×
- WACC
- 13.2%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | STLN | S&P 500 | Difference | STLN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -36.7% | -2.4% | −34.2 pts | ||
| 3 months | -32.2% | -1.2% | −31.1 pts | ||
| Year to date | +18.0% | +12.3% | +5.7 pts | ||
| 1 year | +25.0% | +12.4% | +12.6 pts | ||
| 3 years | +70.0% | +78.8% | −8.8 pts | +19.4% | +21.4% |
| 5 years | -58.4% | +75.2% | −133.6 pts | -16.1% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Starling Oncology filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Update
- Update
- Results
About Starling Oncology
Services-Offices & Clinics of Doctors of Medicine
The Oncology Institute, Inc. delivers outpatient medical and radiation oncology care alongside specialty pharmacy and clinical research services. The company provides treatments such as in-house infusion, radiation therapy, and blood product transfusions, operating through patient services, pharmacy distribution, and clinical trial management. It delivers care under fee-for-service arrangements and value-based risk contracts, including capitation and full delegation models where it assumes administrative functions such as utilization management and claims processing. Its customer base includes commercial and government healthcare payors, Medicare Advantage plans, Medicaid, managed care organizations, and adult cancer patients.
Company profile, executives and historyStarling Oncology stock: common questions
What is Starling Oncology's stock price?
STLN closed at $4.20 on Nov 11, 2026, down 3.23% on the day. Over the past 52 weeks it traded between $2.32 and $7.13.
What is Starling Oncology's market cap?
Starling Oncology was worth $428.05M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is STLN's P/E ratio?
Starling Oncology lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.29), so it has no meaningful P/E ratio.
How much revenue does Starling Oncology make?
Starling Oncology reported revenue of $620.45M for the twelve months to Sep 30, 2026, up 34.6% from a year earlier.
Does Starling Oncology pay a dividend?
No. Starling Oncology has not paid a cash dividend over the last twelve months.
When does Starling Oncology report earnings next?
Starling Oncology is expected to report Q4 FY2026 results on Mar 11, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has STLN stock performed over the past year?
Including dividends, STLN returned +25.0% over the past year, against +12.4% for the S&P 500.
Who are Starling Oncology's competitors?
Companies most similar to Starling Oncology by business, industry and size include CCM, SBC, LFMD, TDOC, AUNA.
See a number that looks wrong?